News >

Goy Reflects on MCL Data Presented at ASH 2017

Angelica Welch
Published: Wednesday, Dec 13, 2017

The mechanism of resistance of CAR T cells is something that we are starting to hear. This is the rationale for a trial we are about to start called ZUMA-6, which is ongoing and looking at axicabtagene ciloleucel (axi-cel; Yescarta) plus atezolizumab (Tecentriq). It is a really exciting time to be at the 2017 ASH Annual Meeting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication